Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8711266 | 0.87 | POLB (0.78) | POLBSMN1; SMN2ALDH1A1HTTLIMK2 | |
| SCHEMBL3274401 | 0.84 | POLB (0.72) | POLBSMN1; SMN2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL2246137 | 0.82 | POLB (0.70) | POLBSMN1; SMN2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL3380247 | 0.82 | POLB (0.68) | POLBALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL7571620 | 0.81 | POLB (0.68) | POLBALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL789616 | 0.81 | KEAP1 (0.72) | POLBALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL7572319 | 0.81 | POLB (0.68) | POLBSMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL7586724 | 0.80 | NPC1 (0.68) | POLBSMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL2835167 | 0.80 | POLB (0.66) | POLBSMN1; SMN2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL23014053 | 0.79 | POLB (0.65) | POLBSMN1; SMN2ALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | POLB 2352/4885SMN1; SMN2 773/4885ALDH1A1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.